Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease

Authors:

Abstract
No abstract available
Funding Information
  • National Key R&D Program of China

This publication has 15 references indexed in Scilit: